Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment.

ABSTRACT: This study enumerated patients' preference-based personal utility and willingness-to-pay for massively parallel sequencing (MPS) genetic testing of colorectal cancer (CRC) risk. Our setting was the New Exome Technology in (NEXT) Medicine Study, a randomized control trial of usual care genetic testing vs. exome sequencing. Using a discrete choice experiment (DCE), we elicited patient preferences for information on genetic causes of CRC. We estimated personal utility for the following four attributes: proportion of individuals with a genetic cause of CRC who receive a diagnosis, number of tests used, wait time for results, and cost. A total of 122 patients completed our DCE (66% response rate). On average, patients preferred genetic tests identifying more individuals with a diagnosis and inv

SUBMITTER: Weymann D 

PROVIDER: S-EPMC6117311 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature